Court Backs Government Power on Patented Drug Access

The Kerala High Court ruled that the Centre can invoke Section 100 of Indian patent law when patented medicines are unaffordable, but left the decision to the government after data collection. The case concerned ribociclib, a breast cancer drug costing ₹58,000 per month. Advocates criticised the lack of a binding directive or deadline, warning of delays in patient access.